These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 15124688)

  • 1. Farnesyltransferase inhibitors (FTIs) in myeloid malignancies.
    Karp JE; Lancet JE
    Ann Hematol; 2004; 83 Suppl 1():S87-8. PubMed ID: 15124688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Farnesyltransferase inhibitors: preliminary results in acute myeloid leukemia].
    Thomas X; Elhamri M
    Bull Cancer; 2005 Mar; 92(3):227-38. PubMed ID: 15820917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy.
    Lancet JE; Karp JE
    Blood; 2003 Dec; 102(12):3880-9. PubMed ID: 12920034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesyl transferase inhibitors in myeloid disorders.
    Lancet JE; Karp JE
    Oncology (Williston Park); 2005 Jul; 19(8):1043-9; discussion 1049-50, 1053-4. PubMed ID: 16131046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Farnesyl transferase inhibitors in myeloid malignancies.
    Lancet JE; Karp JE
    Blood Rev; 2003 Sep; 17(3):123-9. PubMed ID: 12818222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome.
    Kurzrock R; Cortes J; Kantarjian H
    Semin Hematol; 2002 Oct; 39(4 Suppl 3):20-4. PubMed ID: 12447848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards combination target-directed chemotherapy for chronic myeloid leukemia: role of farnesyl transferase inhibitors.
    Daley GQ
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):11-4. PubMed ID: 12783369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.
    Braun T; Fenaux P
    Br J Haematol; 2008 May; 141(5):576-86. PubMed ID: 18410457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Farnesyltransferase inhibitors as anticancer agents: current status.
    Zhu K; Hamilton AD; Sebti SM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1428-35. PubMed ID: 14763128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations.
    Brunner TB; Hahn SM; Gupta AK; Muschel RJ; McKenna WG; Bernhard EJ
    Cancer Res; 2003 Sep; 63(18):5656-68. PubMed ID: 14522880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perspectives on farnesyl transferase inhibitors in cancer therapy.
    Mazieres J; Pradines A; Favre G
    Cancer Lett; 2004 Apr; 206(2):159-67. PubMed ID: 15013521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of farnesyltransferase inhibitors in hematologic malignancies.
    Santos ES; Rosenblatt JD; Goodman M
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):843-56. PubMed ID: 15485318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer.
    Graaf MR; Richel DJ; van Noorden CJ; Guchelaar HJ
    Cancer Treat Rev; 2004 Nov; 30(7):609-41. PubMed ID: 15531395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Farnesyltransferase inhibitor therapy in acute myelogenous leukemia.
    Gotlib J
    Curr Hematol Rep; 2005 Jan; 4(1):77-84. PubMed ID: 15610664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Farnesyltransferase inhibitors in myelodysplastic syndrome.
    Feldman EJ
    Curr Hematol Rep; 2005 May; 4(3):186-90. PubMed ID: 15865870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.
    Karp JE; Lancet JE
    Cancer Invest; 2007 Sep; 25(6):484-94. PubMed ID: 17882662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of signaling in myelodysplastic syndrome.
    Gore SD
    Best Pract Res Clin Haematol; 2004 Dec; 17(4):613-22. PubMed ID: 15494298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.
    Morgan MA; Ganser A; Reuter CW
    Leukemia; 2003 Aug; 17(8):1482-98. PubMed ID: 12886235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Farnesyl transferase inhibitors: one target may be found in another].
    Mazières J; Pradines A; Favre G
    Med Sci (Paris); 2003 Feb; 19(2):211-6. PubMed ID: 12836615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.